Evidence map›Paper›PMID 25232742›Full record

ArticlePLoS pathogens2014

LprG-mediated surface expression of lipoarabinomannan is essential for virulence of Mycobacterium tuberculosis.

Rajiv L Gaur, Kangning Ren, Antje Blumenthal, Suresh Bhamidi, Fernando D González-Nilo, Sara Gibbs, Mary Jackson, Richard N Zare, Sabine Ehrt, Joel D Ernst and 1 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 53 papers.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 95 citations in OpenAlex.

  1. Article
  2. Article
  3. Protein-Mediated Virulence in Mycobacterium tuberculosis.Advances in experimental medicine and biology · 2026
    Review
  4. Secreted proteins ofFrontiers in tuberculosis · 2026
    Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Metabolic Versatility ofMetabolites · 2021
    Review
  18. Advancing Adjuvants forFrontiers in immunology · 2021
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Rajiv L GaurDepartment of Pathology, Stanford University, Stanford, California, United States of America.
Kangning RenDepartment of Chemistry, Stanford University, Stanford, California, United States of America.
Antje BlumenthalDepartment of Microbiology and Immunology, Weill Cornell Medical College, New York City, New York, United States of America.
Suresh BhamidiMycobacteria Research Laboratories, Colorado State University, Fort Collins, Colorado, United States of America.
Fernando D González-Nilo
Sara GibbsMycobacteria Research Laboratories, Colorado State University, Fort Collins, Colorado, United States of America.
Mary JacksonMycobacteria Research Laboratories, Colorado State University, Fort Collins, Colorado, United States of America; Department of Microbiology, Colorado State University, Fort Collins, Colorado, United States of America; Department of Immunology, Colorado State University, Fort Collins, Colorado, United States of America; Department of Pathology, Colorado State University, Fort Collins, Colorado, United States of America.
Richard N ZareDepartment of Chemistry, Stanford University, Stanford, California, United States of America.
Sabine EhrtDepartment of Microbiology and Immunology, Weill Cornell Medical College, New York City, New York, United States of America.
Joel D ErnstDepartment of Pathology, New York University School of Medicine, New York City, New York, United States of America; Division of Infectious Diseases, Department of Medicine, New York University School of Medicine, New York City, New York, United States of America; Department of Microbiology, New York University School of Medicine, New York City, New York, United States of America.
Niaz BanaeiDepartment of Pathology, Stanford University, Stanford, California, United States of America; Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University, Stanford, California, United States of America.
Stanford University · USColorado State University · USCornell University · USNew York University · US

Funding

Initiation of the Immune Response to M. tuberculosisR01AI051242 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ERNST, JOEL D. · 2002 to 2019
$8.3M
Biogenesis of Lipoarabinomannan in MycobacteriaR01AI064798 · NIAID · COLORADO STATE UNIVERSITY-FORT COLLINS · PI JACKSON, MARY · 2005 to 2019
$5.4M
NIAID NIH HHS AI064798NIAID NIH HHS R01 AI064798
6 · The paper itself

Abstract

Mycobacterium tuberculosis employs various virulence strategies to subvert host immune responses in order to persist and cause disease. Interaction of M. tuberculosis with mannose receptor on macrophages via surface-exposed lipoarabinomannan (LAM) is believed to be critical for cell entry, inhibition of phagosome-lysosome fusion, and intracellular survival, but in vivo evidence is lacking. LprG, a cell envelope lipoprotein that is essential for virulence of M. tuberculosis, has been shown to bind to the acyl groups of lipoglycans but the role of LprG in LAM biosynthesis and localization remains unknown. Using an M. tuberculosis lprG mutant, we show that LprG is essential for normal surface expression of LAM and virulence of M. tuberculosis attributed to LAM. The lprG mutant had a normal quantity of LAM in the cell envelope, but its surface was altered and showed reduced expression of surface-exposed LAM. Functionally, the lprG mutant was defective for macrophage entry and inhibition of phagosome-lysosome fusion, was attenuated in macrophages, and was killed in the mouse lung with the onset of adaptive immunity. This study identifies the role of LprG in surface-exposed LAM expression and provides in vivo evidence for the essential role surface LAM plays in M. tuberculosis virulence. Findings have translational implications for therapy and vaccine development.

Indexed as

AnimalsBacterial ProteinsCell WallImmunoblottingLipopolysaccharidesLipoproteinsLungMacrophagesMiceMice, Inbred C57BLMutationMycobacterium tuberculosisPhagocytosisTuberculosisVirulenceBacterial ProteinslipoarabinomannanLipopolysaccharidesLipoproteins

Identifiers

PMID25232742
PMCPMC4169494
OpenAlexW1994646782

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.